Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, vaccine maker Novavax (NASDAQ:NVAX) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Novavax's business, and see what CAPS investors are saying about the stock right now.

Novavax facts

Headquarters (founded)

Rockville, Md. (1987)

Market Cap

$122.56 million



TTM Revenue

$1.06 million


CEO Dr. Rahul Singhvi
Chief Medical Officer Penny Heaton

Return on Equity (average, last three years)


2-Month Return



GlaxoSmithKline (NYSE:GSK)
Merck (NYSE:MRK)

CAPS members bearish on NVAX also bearish on

General Motors (NYSE:GM)

CAPS members bullish on NVAX also bullish on

Johnson & Johnson (NYSE:JNJ)
General Electric (NYSE:GE)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 64 of the 91 All-Star members who have rated Novavax -- some 70% -- believe the stock will underperform the S&P 500 going forward. These bears include JakilaTheHun and TSIF, both of whom are ranked in the top 1% of our community.

Last week, JakilaTheHun brought Novavax's flu-fueled stock price to our community's attention: "Shorting the swine flu bounce. Not necessarily a bad company --- just trading at an unsustainable price for the short-term."

In a pitch from the same day, TSIF expands on that bearish reasoning:

Novavax currently has no products to address any of the infectious diseases and their share price spike is clearly speculative. Its "virus-like particle platform technology" is being applied to the H5N1 and other avian influenza, human seasonal influenza and respiratory [viruses]. It's $0.80 to $1.60 52 week share price has little reason to spike with no products, though funding might be easier to obtain as products are developed. If the swine flu continues to make news then this is a bad call on my part, but overall, I'm hoping and praying on the side of the populace.

What do you think about Novavax, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor recommendation. The Fool's disclosure policy always gets a perfect score.